- Home
- GRCE vs NTIP Comparison
GRCE vs NTIP Comparison
Compare GRCE & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- NTIP
- Stock Information
- Founded
- GRCE 2002
- NTIP 1990
- Country
- GRCE United States
- NTIP United States
- Employees
- GRCE N/A
- NTIP N/A
- Industry
- GRCE
- NTIP Multi-Sector Companies
- Sector
- GRCE
- NTIP Miscellaneous
- Exchange
- GRCE NYSE
- NTIP Nasdaq
- Market Cap
- GRCE 32.1M
- NTIP 31.9M
- IPO Year
- GRCE N/A
- NTIP 1998
- Fundamental
- Price
- GRCE $2.31
- NTIP $1.30
- Analyst Decision
- GRCE Strong Buy
- NTIP
- Analyst Count
- GRCE 1
- NTIP 0
- Target Price
- GRCE $12.00
- NTIP N/A
- AVG Volume (30 Days)
- GRCE 27.5K
- NTIP 8.3K
- Earning Date
- GRCE 05-15-2025
- NTIP 05-09-2025
- Dividend Yield
- GRCE N/A
- NTIP 7.69%
- EPS Growth
- GRCE N/A
- NTIP N/A
- EPS
- GRCE N/A
- NTIP N/A
- Revenue
- GRCE N/A
- NTIP $100,000.00
- Revenue This Year
- GRCE N/A
- NTIP N/A
- Revenue Next Year
- GRCE N/A
- NTIP N/A
- P/E Ratio
- GRCE N/A
- NTIP N/A
- Revenue Growth
- GRCE N/A
- NTIP N/A
- 52 Week Low
- GRCE $2.07
- NTIP $1.22
- 52 Week High
- GRCE $4.97
- NTIP $2.13
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- NTIP 41.36
- Support Level
- GRCE N/A
- NTIP $1.26
- Resistance Level
- GRCE N/A
- NTIP $1.39
- Average True Range (ATR)
- GRCE 0.00
- NTIP 0.05
- MACD
- GRCE 0.00
- NTIP -0.01
- Stochastic Oscillator
- GRCE 0.00
- NTIP 32.23
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.